candesartan cilexetil has been researched along with Insulin Resistance in 9 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to determine whether acute treatment with candesartan cilexetil (CV-11974), an angiotensin II type 1 receptor blocker (ARB) can improve insulin sensitivity in high-fructose-diet (HFD)-fed rats." | 7.78 | Acute treatment with candesartan cilexetil, an angiotensin II type 1 receptor blocker, improves insulin sensitivity in high-fructose-diet-fed rats. ( Jiang, HY; Kawata, Y; Koike, T; Li, P; Oshida, Y; Wang, ZH, 2012) |
| "We have previously demonstrated that captopril ameliorates glucose intolerance by partially preventing the reduction in postprandial skeletal muscle blood flow." | 7.69 | Bradykinin may not be involved in improvement of insulin resistance by angiotensin converting enzyme inhibitor. ( Chen, S; Ishii, J; Kashiwabara, H; Katayama, S; Kosegawa, I, 1996) |
| "This study was designed to investigate the effects of angiotensin II (AII) receptor antagonist and angiotensin converting enzyme (ACE) inhibitor on insulin resistance, and the mechanism by which ACE inhibitor improves insulin-dependent glucose uptake (insulin sensitivity) in an insulin-resistant hypertensive rat model (fructose-fed rats, FFR) and in essential hypertensives (EHT)." | 5.08 | Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. ( Higashiura, K; Hirata, A; Iimura, O; Masuda, A; Matsuda, K; Miyazaki, Y; Nakagawa, M; Shimamoto, K; Takizawa, H; Ura, N, 1995) |
| "This study was to determine whether combination of the angiotensin II AT1 receptor blocker (ARB), candesartan cilexetil, and exercise training can prevent the development of high-fat diet-induced insulin resistance." | 3.78 | Effects of angiotensin II AT1 receptor inhibition and exercise training on insulin action in rats on high-fat diet. ( Chen, T; Jiang, H; Koike, T; Li, P; Mu, L; Natsume, Y; Oshida, Y; Wang, Z, 2012) |
| "We aimed to determine whether acute treatment with candesartan cilexetil (CV-11974), an angiotensin II type 1 receptor blocker (ARB) can improve insulin sensitivity in high-fructose-diet (HFD)-fed rats." | 3.78 | Acute treatment with candesartan cilexetil, an angiotensin II type 1 receptor blocker, improves insulin sensitivity in high-fructose-diet-fed rats. ( Jiang, HY; Kawata, Y; Koike, T; Li, P; Oshida, Y; Wang, ZH, 2012) |
| "We have previously demonstrated that captopril ameliorates glucose intolerance by partially preventing the reduction in postprandial skeletal muscle blood flow." | 3.69 | Bradykinin may not be involved in improvement of insulin resistance by angiotensin converting enzyme inhibitor. ( Chen, S; Ishii, J; Kashiwabara, H; Katayama, S; Kosegawa, I, 1996) |
| "We investigated whether troglitazone (CS-045, an insulin sensitizer) has an antihypertensive effect in fructose (FRU)-fed Wistar rats with insulin resistance and simultaneously compared its hypotensive efficacy with those of alacepril (ALA, an angiotensin converting enzyme inhibitor) and TCV-116 (an AT1a receptor antagonist)." | 3.69 | A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone. ( Chen, S; Izumida, T; Katayama, S; Noguchi, Y; Tatebe, J, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Z | 1 |
| Koike, T | 2 |
| Li, P | 2 |
| Jiang, H | 1 |
| Natsume, Y | 1 |
| Mu, L | 1 |
| Chen, T | 1 |
| Oshida, Y | 2 |
| Jiang, HY | 1 |
| Wang, ZH | 1 |
| Kawata, Y | 1 |
| Hashikawa-Hobara, N | 1 |
| Hashikawa, N | 1 |
| Inoue, Y | 1 |
| Sanda, H | 1 |
| Zamami, Y | 1 |
| Takatori, S | 1 |
| Kawasaki, H | 1 |
| Hamada, N | 1 |
| Nishi, Y | 1 |
| Tajiri, Y | 1 |
| Setoyama, K | 1 |
| Kamimura, R | 1 |
| Miyahara, K | 1 |
| Nuruki, N | 1 |
| Hosoda, H | 1 |
| Kangawa, K | 1 |
| Kojima, M | 1 |
| Mifune, H | 1 |
| Iimura, O | 2 |
| Shimamoto, K | 2 |
| Matsuda, K | 2 |
| Masuda, A | 1 |
| Takizawa, H | 2 |
| Higashiura, K | 2 |
| Miyazaki, Y | 1 |
| Hirata, A | 1 |
| Ura, N | 2 |
| Nakagawa, M | 1 |
| Chen, S | 2 |
| Kashiwabara, H | 1 |
| Kosegawa, I | 1 |
| Ishii, J | 1 |
| Katayama, S | 2 |
| Noguchi, Y | 1 |
| Izumida, T | 1 |
| Tatebe, J | 1 |
| Trenkwalder, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of PPAR Gamma Agonist-Rosiglitazone in Normotensive Type 2 Diabetics With Ambulatory Blood Pressure Monitoring[NCT00290394] | Phase 4 | 25 participants | Interventional | 2004-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for candesartan cilexetil and Insulin Resistance
| Article | Year |
|---|---|
Efficacy and tolerability of candesartan cilexetil in special patient groups.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Heart | 2000 |
1 trial available for candesartan cilexetil and Insulin Resistance
| Article | Year |
|---|---|
Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1995 |
7 other studies available for candesartan cilexetil and Insulin Resistance
| Article | Year |
|---|---|
Effects of angiotensin II AT1 receptor inhibition and exercise training on insulin action in rats on high-fat diet.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2012 |
Acute treatment with candesartan cilexetil, an angiotensin II type 1 receptor blocker, improves insulin sensitivity in high-fructose-diet-fed rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; | 2012 |
Candesartan cilexetil improves angiotensin II type 2 receptor-mediated neurite outgrowth via the PI3K-Akt pathway in fructose-induced insulin-resistant rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; | 2012 |
Disrupted regulation of ghrelin production under antihypertensive treatment in spontaneously hypertensive rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type | 2012 |
Effects of an angiotensin II receptor antagonist, TCV-116, on insulin sensitivity in fructose-fed rats.
Topics: Angiotensin Receptor Antagonists; Animal Feed; Animals; Antihypertensive Agents; Benzimidazoles; Bip | 1994 |
Bradykinin may not be involved in improvement of insulin resistance by angiotensin converting enzyme inhibitor.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1996 |
A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 1996 |